Merck & Co., Inc. (MRK)
NYSE
Market Cap
$333.06B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
430 of 809
Rank in Industry
7 of 10
Largest Insider Buys in Sector
MRK Stock Price History Chart
MRK Stock Performance
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Activity of Merck & Co., Inc.
Over the last 12 months, insiders at Merck & Co., Inc. have bought $0 and sold $57.38M worth of Merck & Co., Inc. stock.
On average, over the past 5 years, insiders at Merck & Co., Inc. have bought $44,336 and sold $117.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3 shares for transaction amount of $341 was made by Romanelli Joseph (President, Human Health Int?l) on 2023‑04‑26.
List of Insider Buy and Sell Transactions, Merck & Co., Inc.
| 2024-02-14 | Sale | Davis Robert M | Chairman, CEO & President | 85,021 0.0034% | $125.40 | $10.66M | +1.78% | |
| 2024-02-14 | Sale | Litchfield Caroline | EVP & CFO | 38,291 0.0015% | $125.50 | $4.81M | +1.78% | |
| 2024-02-13 | Sale | Davis Robert M | Chairman, CEO & President | 150,000 0.0059% | $125.85 | $18.88M | +2.04% | |
| 2024-02-13 | Sale | Romanelli Joseph | President, Human Health Int?l | 1,000 <0.0001% | $124.89 | $124,888 | +2.04% | |
| 2024-02-09 | Sale | Li Dean Y | Executive VP & President, MRL | 14,702 0.0006% | $125.50 | $1.85M | +2.02% | |
| 2024-02-07 | Sale | Williams David Michael | EVP,Chief Info&Digital Officer | 1,451 <0.0001% | $127.57 | $185,108 | +0.25% | |
| 2024-02-02 | Sale | Zachary Jennifer | EVP, General Counsel | 49,499 0.002% | $126.97 | $6.28M | +0.95% | |
| 2024-02-02 | Sale | MIZELL STEVEN | EVP, Chief HR Officer | 50,694 0.0021% | $126.65 | $6.42M | +0.95% | |
| 2024-02-02 | Sale | Oosthuizen Johannes Jacobus | President, U.S. Market | 18,959 0.0008% | $127.17 | $2.41M | +0.95% | |
| 2023-11-09 | Sale | Oosthuizen Johannes Jacobus | President, U.S. Market | 2,081 <0.0001% | $102.38 | $213,061 | +22.53% | |
| 2023-11-08 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 43,823 0.0017% | $105.03 | $4.6M | +19.96% | |
| 2023-08-14 | Sale | MIZELL STEVEN | EVP, Chief HR Officer | 4,250 0.0002% | $109.01 | $463,293 | +9.07% | |
| 2023-08-03 | Sale | MIZELL STEVEN | EVP, Chief HR Officer | 4,500 0.0002% | $105.49 | $474,701 | +12.01% | |
| 2023-08-02 | Sale | Romanelli Joseph | President, Human Health Int?l | 89 <0.0001% | $107.37 | $9,556 | +12.02% | |
| 2023-05-04 | Sale | Karachun Rita A | Sr. VP Fince-Global Controller | 15,875 0.0006% | $117.53 | $1.87M | -5.86% | |
| 2023-05-04 | Sale | Zachary Jennifer | EVP, General Counsel | 19,141 0.0008% | $117.59 | $2.25M | -5.86% | |
| 2023-05-03 | Sale | MIZELL STEVEN | EVP, Chief HR Officer | 53,400 0.0021% | $119.01 | $6.36M | -6.47% | |
| 2023-05-02 | Sale | Williams David Michael | EVP,Chief Info&Digital Officer | 7,509 0.0003% | $116.82 | $877,222 | -6.21% | |
| 2023-05-01 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 75,436 0.003% | $116.03 | $8.75M | -4.96% | |
| 2023-04-28 | Sale | Davis Robert M | Chairman, CEO & President | 143,329 0.0056% | $114.93 | $16.47M | -4.38% |
Insider Historical Profitability
4.24%
| Davis Robert M | Chairman, CEO & President | 348327 0.0107% | $131.50 | 0 | 7 | |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 111764 0.0044% | $131.50 | 0 | 10 | |
| Li Dean Y | Executive VP & President, MRL | 46242 0.0018% | $131.50 | 0 | 1 | |
| Zachary Jennifer | EVP, General Counsel | 29058 0.0011% | $131.50 | 0 | 4 | |
| Litchfield Caroline | EVP & CFO | 50908 0.001% | $131.50 | 0 | 2 | |
| MIZELL STEVEN | EVP, Chief HR Officer | 23619 0.0009% | $131.50 | 0 | 9 | |
| Oosthuizen Johannes Jacobus | President, U.S. Market | 23327 0.0009% | $131.50 | 0 | 5 | |
| Williams David Michael | EVP,Chief Info&Digital Officer | 19812 0.0008% | $131.50 | 0 | 2 | |
| Romanelli Joseph | President, Human Health Int?l | 19569 0% | $131.50 | 8 | 4 | +0.2% |
| HASSAN FRED | Chairman and CEO | 720800 0.0284% | $131.50 | 2 | 0 | <0.0001% |
| FRAZIER KENNETH C | Executive Chair | 700653 0.0276% | $131.50 | 1 | 40 | +21.77% |
| SABATINO THOMAS J JR | Executive Vice President | 309535 0.0122% | $131.50 | 1 | 0 | |
| KIM PETER S | Exe V-P & Pres, MRL | 170706 0.0067% | $131.50 | 0 | 1 | |
| Kuhlik Bruce N | Exe V-P & Gen Counsel | 150432 0.0059% | $131.50 | 0 | 6 | |
| PERLMUTTER ROGER M | Exe V-P & Pres, MRL | 141555 0.0056% | $131.50 | 0 | 1 | |
| Deese Willie A | Exe V-P & Pres. MMD | 106230 0.0042% | $131.50 | 0 | 7 | |
| Clyburn Frank | EVP & Pres ? Human Health | 97095 0.0038% | $131.50 | 0 | 4 | |
| COX CARRIE SMITH | Executive Vice President | 91205 0.0036% | $131.50 | 0 | 2 | |
| GRADDICK WEIR MIRIAN M | Exe V-P, HR | 80433 0.0032% | $131.50 | 0 | 7 | |
| KOHAN RAUL E | Exe V-P & Pres, Animal Health | 78167 0.0031% | $131.50 | 0 | 9 | |
| Bowles Richard S III | Exe VP&Chief Ethics & ComplOff | 73540 0.0029% | $131.50 | 0 | 5 | |
| BARSHAY STANLEY F | ExVP&PresConsHlthCare | 71589 0.0028% | $131.50 | 0 | 3 | |
| PICKETT CECIL B | Vice President | 68541 0.0027% | $131.50 | 0 | 4 | |
| BERTOLINI ROBERT J | Executive Vice President | 65000 0.0026% | $131.50 | 1 | 0 | |
| RYAN JOHN P | Senior Vice President | 52923 0.0021% | $131.50 | 0 | 1 | |
| KELLOGG PETER N | Exe V-P & CFO | 53999 0.0021% | $131.50 | 1 | 0 | +24.74% |
| Holston Michael J | EVP, General Counsel | 49092 0.0019% | $131.50 | 0 | 4 | |
| Karachun Rita A | Sr. VP Fince-Global Controller | 45710 0.0018% | $131.50 | 0 | 6 | |
| CHEELEY C RON | Senior Vice President | 40344 0.0016% | $131.50 | 0 | 3 | |
| Gerberding Julie L. | EVP, Chief Patient Officer | 39162 0.0015% | $131.50 | 0 | 7 | |
| SAUNDERS BRENT L | Senior Vice President | 30930 0.0012% | $131.50 | 0 | 1 | |
| Heller Bridgette P | Exe.VP & Pres.Con.Hlth.Care | 27587 0.0011% | $131.50 | 0 | 3 | |
| AMBROSE ADELE D | Sr.V-P & Chief Comuns Officer | 17876 0.0007% | $131.50 | 0 | 4 | |
| Golestani Clark | EVP & Chief Info Officer | 14083 0.0006% | $131.50 | 0 | 5 | |
| Colligan Thomas J | director | 15024 0.0006% | $131.50 | 2 | 0 | +16.75% |
| RUSSO PATRICIA F | director | 13148 0.0005% | $131.50 | 0 | 1 | |
| Canan John | Sr.V-P Finc-Global Controller | 10697 0.0004% | $131.50 | 0 | 2 | |
| STAHL JACK L | director | 10000 0.0004% | $131.50 | 2 | 0 | <0.0001% |
| Watson Ashley | SVP Chief Ethics & Com Officer | 9770 0.0004% | $131.50 | 0 | 1 | |
| KIDDER C ROBERT | director | 9317 0.0004% | $131.50 | 0 | 1 | |
| GLOCER THOMAS H | director | 5100 0.0002% | $131.50 | 0 | 2 | |
| LAZARUS ROCHELLE B | director | 4594 0.0002% | $131.50 | 0 | 2 | |
| BRUN LESLIE A | director | 1948 0.0001% | $131.50 | 0 | 2 | |
| Cech Thomas R | director | 100 0% | $131.50 | 0 | 2 | |
| WEEKS WENDELL P | director | 100 0% | $131.50 | 0 | 8 | |
| WENDELL PETER C | director | 1000 0% | $131.50 | 0 | 5 | |
| Schechter Adam H | EVP & Pres-Global Human Health | 0 0% | $131.50 | 0 | 15 | |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD | 0 0% | $131.50 | 0 | 7 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| The Vanguard Group | $32.1B | 9.61 | 243.27M | -0.62% | -$198.83M | 0.61 | |
| BlackRock | $27.32B | 8.17 | 207.02M | +2.57% | +$683.37M | 0.62 | |
| State Street | $15.58B | 4.64 | 117.43M | +0.48% | +$74.26M | 0.67 | |
| Wellington Management Company | $11.39B | 3.41 | 86.35M | +0.88% | +$99.26M | 1.93 | |
| Geode Capital Management | $7.43B | 2.23 | 56.41M | +1.77% | +$129.4M | 0.67 | |
| Fidelity Investments | $6.88B | 2.06 | 52.17M | +21.89% | +$1.24B | 0.46 | |
| Morgan Stanley | $5.48B | 1.64 | 41.51M | +3.43% | +$181.57M | 0.42 | |
| Bank of America | $4.75B | 1.42 | 36.01M | -5.22% | -$261.61M | 0.46 | |
| T. Rowe Price | $3.91B | 1.17 | 29.64M | -1.49% | -$59.07M | 0.48 | |
| Northern Trust | $3.58B | 1.07 | 27.1M | -4.89% | -$183.68M | 0.61 | |
| JPMorgan Chase | $3.52B | 1.05 | 26.66M | +4.92% | +$165.07M | 0.32 | |
| Legal & General | $3.08B | 0.92 | 23.38M | -0.49% | -$15.24M | 0.72 | |
| Deutsche Bank | $2.8B | 0.84 | 21.24M | -1.53% | -$43.63M | 1.28 | |
| BNY Mellon | $2.59B | 0.78 | 19.64M | -5.7% | -$156.62M | 0.49 | |
| Franklin Templeton Investments | $2.33B | 0.7 | 17.69M | +74.93% | +$1B | 0.7 | |
| Charles Schwab | $2.29B | 0.7 | 17.65M | -51.88% | -$2.47B | 0.52 | |
| Ameriprise Financial | $2.24B | 0.67 | 16.97M | +3.4% | +$73.67M | 0.62 | |
| Nuveen | $2.18B | 0.65 | 16.54M | -0.95% | -$20.88M | 0.64 | |
| Wells Fargo | $2.16B | 0.65 | 16.38M | +0.7% | +$15.07M | 0.58 | |
| Invesco | $2.12B | 0.63 | 16.06M | -4.17% | -$92.24M | 0.45 | |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $1.94B | 0.58 | 14.7M | +22% | +$349.8M | 2.2 | |
| Capital World Investors | $1.84B | 0.55 | 13.95M | +67.59% | +$742.6M | 0.31 | |
| Fisher Asset Management Llc | $1.83B | 0.55 | 13.87M | +2.36% | +$42.12M | 0.86 | |
| State Farm | $1.82B | 0.55 | 13.79M | 0% | +$0 | 1.64 | |
| Royal Bank of Canada | $1.8B | 0.54 | 13.6M | -9.13% | -$180.48M | 0.43 | |
| UBS | $1.79B | 0.53 | 13.54M | +6.94% | +$115.92M | 0.54 | |
| Amundi | $1.59B | 0.5 | 12.67M | +2.33% | +$36.08M | 0.67 | |
| Ubs Asset Management Americas Inc | $1.66B | 0.5 | 12.55M | -0.97% | -$16.18M | 0.59 | |
| Goldman Sachs | $1.54B | 0.46 | 11.66M | -3.72% | -$59.38M | 0.29 | |
| AllianceBernstein | $1.48B | 0.44 | 11.19M | +24.33% | +$288.89M | 0.52 | |
| CalPERS | $1.45B | 0.44 | 11.01M | -15.24% | -$261.27M | 1.02 | |
| Massachusetts Financial Services Co Ma | $1.44B | 0.43 | 10.89M | -4.74% | -$71.49M | 0.43 | |
| Janus Henderson | $1.38B | 0.41 | 10.46M | -13.23% | -$210.55M | 0.75 | |
| Millennium Management LLC | $1.33B | 0.4 | 10.07M | +66.49% | +$530.64M | 0.94 | |
| Raymond James Associates | $1.29B | 0.39 | 9.8M | +2.19% | +$27.66M | 0.87 | |
| Aristotle | $1.21B | 0.36 | 9.19M | -3.08% | -$38.59M | 2.32 | |
| Schroder Investment Management Group | $1.17B | 0.35 | 8.84M | +17.1% | +$170.26M | 1.38 | |
| Barclays | $1.14B | 0.34 | 8.67M | +58.38% | +$421.78M | 0.52 | |
| PNC Financial Services | $1.12B | 0.33 | 8.45M | -3.89% | -$45.15M | 0.78 | |
| Nordea Investment Management Ab | $1.1B | 0.33 | 8.36M | +0.68% | +$7.47M | 1.3 | |
| Envestnet Asset Management Inc | $1.01B | 0.3 | 7.63M | +6.56% | +$61.94M | 0.4 | |
| Swiss National Bank | $1B | 0.3 | 7.59M | -4.36% | -$45.64M | 0.68 | |
| Citadel Advisors LLC | $999.55M | 0.3 | 7.58M | +19.9% | +$165.87M | 0.65 | |
| HSBC | $979.7M | 0.29 | 7.43M | +11.23% | +$98.93M | 0.7 | |
| Sumitomo Mitsui Trust Holdings | $932.92M | 0.28 | 7.07M | +4.37% | +$39.07M | 0.64 | |
| Stifel | $928.68M | 0.28 | 7.04M | +3.54% | +$31.75M | 1.08 | |
| ClearBridge Investments | $927.38M | 0.28 | 7.03M | -1.51% | -$14.23M | 0.74 | |
| LSV Asset Management | $922.04M | 0.28 | 6.99M | -6.44% | -$63.51M | 1.92 | |
| Bank of Montreal | $866.92M | 0.26 | 6.58M | -12.98% | -$129.35M | 0.27 | |
| Credit Suisse | $829.65M | 0.25 | 6.29M | -3.5% | -$30.07M | 0.76 |